No Data
No Data
Dezhan Healthcare: 2024 Interim Performance Forecast
Dezhan Healthcare (000813.SZ): Expected to have a profit of 8-12 million yuan in the first half of the year.
On July 10th, Grong Hui reported Dezhan Healthcare's (000813.SZ) performance forecast for the first half of 2024. The net income attributable to shareholders of the listed company is expected to be between 8 million yuan and 12 million yuan, which is a significant increase from the loss of 7.5644 million yuan in the same period last year. The net income after deducting non-recurring gains and losses is expected to be between 6.5 million yuan and 9.5 million yuan, compared to a loss of 8.8348 million yuan in the same period last year. The basic earnings per share is expected to be between 0.0037 yuan/share and 0.0055 yuan/share. The company's revenue has increased year-on-year during the reporting period, while the impairment loss of inventory has decreased compared to the previous period, thus greatly improving the overall financial performance of the company.
Dezhan Healthcare (000813.SZ) plans to spend 200-300 million yuan to repurchase shares.
On July 2nd, Gelonhui reported that Dezhan Healthcare (000813.SZ) plans to repurchase the company's issued renminbi ordinary shares (A shares), for the purpose of canceling and reducing the registered capital; the total amount of funds for repurchase is not less than RMB 200 million and not more than RMB 300 million; the price range for this repurchase of shares is no more than RMB 3.59 per share. The implementation period is within 12 months from the date of approval of the share repurchase plan by the shareholders' meeting.
Subdued Growth No Barrier To Dezhan Healthcare Company Limited's (SZSE:000813) Price
When close to half the companies in the Pharmaceuticals industry in China have price-to-sales ratios (or "P/S") below 2.9x, you may consider Dezhan Healthcare Company Limited (SZSE:000813) as a stock
Dezhan Health (000813.SZ): No products or technologies related to the field of cellular immunotherapy are currently involved
Gelonghui, May 10 | Dezhan Health (000813.SZ) said on the investor interactive platform that the company is currently not involved in products or technologies related to the field of cellular immunotherapy.
Dezhan Health (000813.SZ): Currently, projects such as simeglutide and recombinant human collagen being developed by the company's subsidiary Hantide Biology involve synthetic biology-related research
Gelonghui, May 10 | Dezhan Health (000813.SZ) said on the investor interactive platform that the company's subsidiary Hantide Biotech is currently developing projects such as simeglutide and recombinant human collagen-like proteins involving synthetic biology-related research. Thank you for your interest. In the future, Hanpeptide Biology will continue to conduct continuous deepening and iterative research in synthetic biology fields such as peptide drugs and recombinant humanized collagen based on synthetic biology.
No Data